Dermatomyositis (Connective Tissue Disease) Clinical Trials

A listing of Dermatomyositis (Connective Tissue Disease) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 187 clinical trials
None
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies.

chloroquine
methotrexate
lupus
arthritis
pericarditis
  • 44 views
  • 29 Sep, 2021
  • 240 locations
None
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to 17 years of age with SLE on a background of standard of care therapy. This bridging …

sirolimus, oral
chloroquine
lupus
cyclosporine
nsaids
  • 2 views
  • 18 Oct, 2021
  • 13 locations
None
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

lupus
  • 503 views
  • 24 Oct, 2021
  • 567 locations
None
A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.

corticosteroids
leflunomide
methotrexate
lupus
mycophenolate
  • 220 views
  • 21 Oct, 2021
  • 231 locations
None
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 or CFZ533 in patients with SLE to enable further development of these compounds as treatment in this disease population

corticosteroids
anti-double stranded dna
DMARD
ds dna
  • 38 views
  • 16 Oct, 2021
  • 38 locations
None
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).

arthritis
rash
antinuclear antibody
lupus
  • 79 views
  • 24 Oct, 2021
  • 152 locations
None
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

corticosteroids
sjogren's syndrome
rheumatism
lupus
immunosuppressive agents
  • 27 views
  • 12 Sep, 2021
  • 160 locations
None
COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL

The COVID-19 pandemic represents a threat to rheumatology patients. National advice for patients to 'shield' is based on risk stratification of therapies and other risk factors. While the epidemiology of COVID-19 in the rheumatological population is largely unknown large case registries are beginning to show potential drug treatment interactions. Strict …

  • 0 views
  • 27 Sep, 2021
  • 1 location
None
A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).

glucocorticoids
chloroquine
lupus
induction therapy
nephritis
  • 261 views
  • 30 Sep, 2021
  • 98 locations
None
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

The primary objective of this study is to determine the safety, and evaluate the efficacy of GS-248 versus placebo on Raynaud's Phenomenon (RP) in subjects with Systemic Sclerosis (SSc).

calcium
raynaud's phenomenon
raynaud's syndrome
arthritis
calcium channel blockers
  • 0 views
  • 12 Aug, 2021
  • 10 locations